FOB debate awaits Kennedy/Enzi bill
Executive Summary
Rep. Henry Waxman's follow-on biologics bill arrives in the Senate March 26, courtesy of Chuck Schumer, D-N.Y., as S. 726, with three Republican and four Democrat co-sponsors, including Schumer. Meanwhile, Waxman is now joined by two Democrats and four Republicans in backing H.R. 1427. This compares to 54 co-sponsors signing on to Rep. Anna Eshoo's H.R. 1548 (1"The Pink Sheet" DAILY, March 18, 2009). Biosimilars legislation reported by the Senate Health, Education, Labor and Pensions Committee in 2008 will be re-introduced by Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., as soon as an agreement is reached on language to clarify how biologics can be modified and still qualify as innovative and gain 12 years of data exclusivity
You may also be interested in...
Biosimilars: How Many Votes Is A Chairmanship Worth?
Eshoo introduces her biosimilars bill with 43 co-sponsors, but Waxman controls the agenda.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.